Pharmacogenetics of pain management in Zimbabwean patients with sickle cell disease.
Nyasha Lorraine MapiraRoslyn Stella ThelingwaniChikwambi ZediasTafadzwa Patience KunongaCollen MasimirembwaPublished in: Pharmacogenomics (2023)
Background: Pain is a common cause of hospitalization in sickle cell disease (SCD) patients. Failure to effectively control pain remains a challenge in patient care. Materials & methods: The authors conducted a cross-sectional study to determine the effect of CYP2D6 and UGT2B7 polymorphisms on pain management in 106 Zimbabwean SCD patients. Participant information was collected on a questionnaire. Genotyping was conducted using the GenoPharm ® pharmacogenomics open array panel containing CYP2D6 and UGT genetic variants implicated in opioid response. Results: The reduced function alleles CYP2D6*17 and *29 had high frequencies of 15.9% and 12.9%, respectively. UGT2B7 rs73823859 showed a statistically significant correlation with pain levels (p = 0.0454). Conclusion: This study demonstrated the role of UGT2B7 polymorphism in SCD patient pain management.
Keyphrases
- pain management
- chronic pain
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- emergency department
- prognostic factors
- genome wide
- neuropathic pain
- sickle cell disease
- physical activity
- dna methylation
- case report
- spinal cord injury
- peritoneal dialysis
- spinal cord
- risk factors
- minimally invasive
- health information
- electronic health record
- high density
- high resolution